by Michael Nevradakis, Ph.D. at the Defender
A military whistleblower released a series of documents revealing 601 deaths of military service members and a high rate of serious adverse events in clinical trials involving remdesivir, an antiviral commonly administered to COVID-19 patients during the pandemic.
According to “The Remdesivir Papers,” some clinical trials were improperly run. In the case of at least one study, results were never made public. The whistleblower also alleged a widespread lack of informed consent for trial participants.
“Data derived from the Department of Defense [DOD] Joint Trauma System … by a military whistleblower offers a stark contrast to results of multiple clinical trials involving the liberal usage of remdesivir in military treatment facilities and other civilian facilities, as well as its potential contribution to, at minimum, hundreds of untimely deaths,” the documents state.
Yet according to the documents, the military began “liberally” administering remdesivir to service members who were suspected of having COVID-19 — months before the U.S. Food and Drug Administration (FDA) approved the drug.
The whistleblower,
Continue Reading